Analyst Ratings For ADMA Biologics Inc (NASDAQ:ADMA)
Today, Maxim Group reiterated its Positive rating on ADMA Biologics Inc (NASDAQ:ADMA) with a price target of $12.00.
There are 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on ADMA Biologics Inc (NASDAQ:ADMA) is Buy with a consensus target price of $9.3750 per share, a potential 56.25% upside.
Some recent analyst ratings include
- 7/26/2018-Maxim Group Reiterated Rating of Positive .
- 7/12/2018-Oppenheimer initiated coverage with a Buy rating.
- 11/14/2017-Raymond James Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
Recent Insider Trading Activity For ADMA Biologics Inc (NASDAQ:ADMA)
ADMA Biologics Inc (NASDAQ:ADMA) has insider ownership of 16.90% and institutional ownership of 37.46%.
- On 6/8/2018 Adam S Grossman, CEO, bought 52,301 with an average share price of $4.78 per share and the total transaction amounting to $249,998.78.
- On 6/8/2018 Brian Lenz, CFO, bought 5,000 with an average share price of $4.78 per share and the total transaction amounting to $23,900.00.
- On 6/8/2018 Jerrold B Grossman, Director, bought 20,921 with an average share price of $4.78 per share and the total transaction amounting to $100,002.38.
- On 11/9/2017 Adam S Grossman, Insider, bought 485,000 with an average share price of $2.15 per share and the total transaction amounting to $1,042,750.00.
- On 11/9/2017 Brian Lenz, CFO, bought 6,500 with an average share price of $2.15 per share and the total transaction amounting to $13,975.00.
- On 11/9/2017 Eric I Richman, Director, bought 25,000 with an average share price of $2.15 per share and the total transaction amounting to $53,750.00.
- On 11/9/2017 James Mond, CMO, bought 10,000 with an average share price of $2.15 per share and the total transaction amounting to $21,500.00.
About ADMA Biologics Inc (NASDAQ:ADMA)
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency. It distributes its products through independent distributors, sales agents, specialty pharmacies, and others. The ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Recent Trading Activity for ADMA Biologics Inc (NASDAQ:ADMA)
Shares of ADMA Biologics Inc closed the previous trading session at 6,00 up +1,06 21,46 % with 6.29 shares trading hands.